U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07737054) titled 'Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD' on July 14.
Brief Summary: This is an open-label pilot study designed to evaluate the safety, tolerability, and preliminary clinical effects of psilocybin-enhanced trauma-focused psychotherapy in individuals with post-traumatic stress disorder (PTSD).
Participants will receive a structured therapeutic protocol that includes preparatory sessions, two psilocybin administration sessions (15 mg followed by 25 mg), and integration sessions based on a trauma-focused therapeutic approach.
The primary objective of the study is to assess the safety and tolerability of psil...